19.04.2020, 4036 Zeichen

Marinomed: Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, reports encouraging developments in the 2019 financial year.  “In 2019, it was not possible to foresee the current strong increase in demand for Carragelose® products. But it shows that we can expect the world to think differently about how to deal with viral infections of the respiratory tract. We believe that as a result of Covid-19, virus blockers will play a decisive role in future. With our technology platforms, we are broadly and optimally positioned for this”, says Andreas Grassauer, CEO of Marinomed, about the current exceptional situation. Carragelose®, developed and patented by Marinomed, is one of the very few active ingredients with clinical data on patients infected with coronaviruses. Already in 2014, the analysis of patients treated with Carragelose® compared to those treated with placebo revealed that the duration of symptoms was three days shorter. Andreas Grassauer states: “Even some years ago, we were able to show that Carragelose® physically binds coronaviruses and thereby reduces the replication of the virus.” Data from laboratory or clinical studies are not yet available for the new Sars-CoV-2 virus. However, Marinomed is well connected into extensive research activities via national and international networks. “Should there be a similar positive effect, we expect to experience continued growth in demand on a global basis”, explains Andreas Grassauer. Currently, Carragelose® products are distributed in more than 40 countries worldwide. The company is therefore working intensively on extending production capacities at its manufacturing partners. In the 2019 financial year, Marinomed was able to increase revenues by 31% to EUR 6.14 million (2018: EUR 4.67 million). These were predominantly realised within the Carragelose® segment. With a clear view on long-term growth targets, Marinomed continues to focus on investments in research and development. These increased to EUR 4.78 million, up from EUR 2.93 million in 2018. The development of results reflects these high investments. The operating result (EBIT) was negative at Euro -6.21 mn as planned (2018: Euro -5.14 mn). The full-year result improved from Euro -12.10 mn to Euro -7.22 mn. Marinomed expects a positive trend in orders and revenues again in 2020. In the first few months of 2020, a significantly higher demand for Carragelose® products was already observed as a result of the SARS-CoV-2 pandemic and is expected to have a positive impact on the trend in revenues. Contrary to this positive effect, there will be pandemic-related short-term delays in the planned studies and applications for marketing authorisation. Due to the continued high expenses for research and development, Marinomed also expects negative operating results for 2020 and subsequent years.
Marinomed Biotech: weekly performance: 3.19%

Agrana: Against the background of the corona crisis, the bioethanol produced at Agrana's site in Pischelsdorf (Tulln District) has recently been approved for use in the manufacture of disinfectants. Besides supplying high-proof alcohol to major customers in the downstream disinfectant manufacturing sector, Agrana itself has also started making surface and hand disinfectants. A share of the disinfectants manufactured will be distributed free-of-charge to care and social organisations in Lower Austria, Upper Austria and Styria. More specifically, these disinfectants, which will be distributed by the relevant site managers, will be donated to institutions located in the vicinity of Agrana facilities in Aschach/ Donau (Upper Austria), Gmünd, Kröllendorf, Leopoldsdorf, Pischelsdorf and Tulln (all in Lower Austria) and in Gleisdorf (Styria). The first handover by the site manager in Kröllendorf to the "Lebenshilfe-Niederösterreich" organisation (Hiesbach) took place earlier today.
Agrana: weekly performance: 2.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (16/04/2020)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #137: Tennis-Highlights, Rankings & Rookies 2024 aus österreichischer Sicht feat. Thomas Schweda, ÖTV

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, voestalpine, Amag, Immofinanz, CA Immo, EuroTeleSites AG, Frequentis, Rosgix, Warimpex, Wienerberger, Kapsch TrafficCom, AT&S, Frauenthal, Gurktaler AG Stamm, Polytec Group, Wolftank-Adisa, Porr, Oberbank AG Stamm, UBM, Palfinger, Zumtobel, Addiko Bank, Agrana, Erste Group, EVN, Flughafen Wien, OMV, Österreichische Post, S Immo, Telekom Austria, Uniqa.

---